Dr Kelly , I dont believe, removed himself from the COB role; I believe his removal as COB coincided with the new head of the board coming on in November of last year. That’s when the other shoe dropped. Kelly was taken out as chairman then a few weeks later NP was let go. I mentioned on this board a few times how having the COB being a subordinate of the CEO was lousy governance and I think I was right . Kelly was hamstrung and having an outside COB is the way all companies should operate . No one was in a position to keep Np in check beforehand and I guess I will go to my grave saying his strategic shift to Covid was what put this company back both from a studies standpoint point and financially . He went for it all at the sacrifice of HIV and others . He also stated during that period that the fact they only had 20 headcount didn’t keep them from doing everything,which I think was bunk.
Now Kelly can focus in on making this an oncology company along with NASH and autoimmune treatments which is it’s future. I have no knock on Dr. Kelly in his role but I had a huge problem with him being the COB and essentially , unable to do that job because of the reporting structure inside Cytodyn. To Dr. lalezari’s credit , he called some of this out when he spoke to the NIH about the poor operation of the company. He was right.